Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

Acta Neuropathologica

Volumn 129, Issue 5, 2015, Pages 669-678

  Korshunov, Andrey ^a,b   Ryzhova, Marina ^c   Hovestadt, Volker ^a   Bender, Sebastian ^a   Sturm, Dominik ^a,b   Capper, David ^a,b   Meyer, Jochen ^a,b   Schrimpf, Daniel ^a,b   Kool, Marcel ^a   Northcott, Paul A ^a   Zheludkova, Olga ^d   Milde, Till ^a,b   Witt, Olaf ^a,b   Kulozik, Andreas E ^a,b   Reifenberger, Guido ^a,e   Jabado, Nada ^f   Perry, Arie ^g   Lichter, Peter ^a   von Deimling, Andreas ^a,b   Pfister, Stefan M ^a,b   Jones, David T W ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^d Chemistry Moscow Russia   (Russian Federation)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF; Brain tumor; CDKN2A; Glioblastoma; Methylation; Pediatric; Prognostic; Subgroup; Survival

Indexed keywords

B RAF KINASE; TUMOR MARKER;

ADOLESCENT; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CELL TRANSFORMATION; CHILD; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOMICS; GLIOBLASTOMA; HUMAN; INFANT; MALE; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ASTROCYTOMA; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; EPIGENOMICS; FEMALE; GENES, P16; GENOMICS; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; MUTATION; NEOPLASM GRADING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA;

EID: 84939973619     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1405-4     Document Type: Article

References (54)

1. Aihara K, Mukasa A, Gotoh K et al (2014) H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro-oncology 16(1):140–146. doi:10.1093/neuonc/not144
2. Bady P, Sciuscio D, Diserens AC et al (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124(4):547–560. doi:10.1007/s00401-012-1016-2
3. Bandopadhayay P, Bergthold G, London WB et al (2014) Long-term outcome of 4040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61(7):1173–1179. doi:10.1002/pbc.24958
4. Bax DA, Mackay A, Little SE et al (2010) A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 16(13):3368–3377. doi:10.1158/1078-0432.CCR-10-0438
5. Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477. doi:10.1016/j.cell.2013.09.034
6. Broniscer A, Tatevossian RG, Sabin ND et al (2014) Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 40(3):327–336. doi:10.1111/nan.12093
7. Buczkowicz P, Hoeman C, Rakopoulos P et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46(5):451–456. doi:10.1038/ng.2936
8. Buttarelli FR, Massimino M, Antonelli M et al (2010) Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas. Childs Nerv Syst 26(8):1051–1056. doi:10.1007/s00381-010-1191-1
9. Ceppa EP, Bouffet E, Griebel R, Robinson C, Tihan T (2007) The pilomyxoid astrocytoma and its relationship to pilocytic astrocytoma: report of a case and a critical review of the entity. J Neurooncol 81(2):191–196. doi:10.1007/s11060-006-9216-z
10. Cohen KJ, Pollack IF, Zhou T et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncology 13(3):317–323. doi:10.1093/neuonc/noq191
11. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48(4):403–407. doi:10.1002/pbc.20803
12. Duffner PK, Horowitz ME, Krischer JP et al (1999) The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-oncology 1(2):152–161
13. Faury D, Nantel A, Dunn SE et al (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol: Off J Am Soc Clin Oncol 25(10):1196–1208. doi:10.1200/JCO.2006.07.8626
14. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J et al (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46(5):462–466. doi:10.1038/ng.2950
15. Frattini V, Trifonov V, Chan JM et al (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45(10):1141–1149. doi:10.1038/ng.2734
16. Haque T, Faury D, Albrecht S et al (2007) Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. Clin Cancer Res 13(21):6284–6292. doi:10.1158/1078-0432.CCR-07-0525
17. Hovestadt V, Remke M, Kool M et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125(6):913–916. doi:10.1007/s00401-013-1126-5
18. Ida CM, Rodriguez FJ, Burger PC et al (2014) Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. doi:10.1111/bpa.12217
19. Jeibmann A, Hasselblatt M, Pfister S et al (2009) From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior. J Neurosurg Pediatr 4(5):475–478. doi:10.3171/2009.6.PEDS097
20. Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14(10):651–661. doi:10.1038/nrc3811
21. Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9(7):400–413. doi:10.1038/nrclinonc.2012.87
22. Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447. doi:10.1007/s00401-012-0998-0
23. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37(5):685–698. doi:10.1097/PAS.0b013e31827f9c5e
24. Koelsche C, Sahm F, Wohrer A et al (2014) BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 24(3):221–229. doi:10.1111/bpa.12111
25. Korshunov A, Sycheva R, Gorelyshev S, Golanov A (2005) Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 18(9):1258–1263. doi:10.1038/modpathol.3800415
26. Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK (2011) MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst 27(11):1877–1883. doi:10.1007/s00381-011-1525-7
27. Lewis PW, Muller MM, Koletsky MS et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340(6134):857–861. doi:10.1126/science.1232245
28. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4
29. Mistry M, Zhukova N, Merico D et al (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol: Off J Am Soc Clin Oncol. doi:10.1200/JCO.2014.58.3922
30. Ostrom QT, Gittleman H, Liao P et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 16(Suppl 4):63. doi:10.1093/neuonc/nou223
31. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. doi:10.1126/science.1164382
32. Paugh BS, Broniscer A, Qu C et al (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol: Off J Am Soc Clin Oncol 29(30):3999–4006. doi:10.1200/JCO.2011.35.5677
33. Paugh BS, Qu C, Jones C et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol: Off J Am Soc Clin Oncol 28(18):3061–3068. doi:10.1200/JCO.2009.26.7252
34. Phillips JJ, Aranda D, Ellison DW et al (2013) PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 23(5):565–573. doi:10.1111/bpa.12043
35. Pollack IF, Finkelstein SD, Burnham J et al (2001) Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 61(20):7404–7407
36. Puget S, Philippe C, Bax DA et al (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7(2):e30313. doi:10.1371/journal.pone.0030313
37. Qu HQ, Jacob K, Fatet S et al (2010) Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-oncology 12(2):153–163. doi:10.1093/neuonc/nop001
38. Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258. doi:10.1186/1471-2407-14-258
39. Schiffman JD, Hodgson JG, VandenBerg SR et al (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512–519. doi:10.1158/0008-5472.CAN-09-1851
40. Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi:10.1007/s00401-011-0802-6
41. Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231. doi:10.1038/nature10833
42. Srivastava A, Jain A, Jha P et al (2010) MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst 26(11):1613–1618. doi:10.1007/s00381-010-1214-y
43. Stokland T, Liu JF, Ironside JW et al (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro-oncology 12(12):1257–1268. doi:10.1093/neuonc/noq092
44. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
45. Sturm D, Bender S, Jones DT et al (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14(2):92–107. doi:10.1038/nrc3655
46. Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437. doi:10.1016/j.ccr.2012.08.024
47. Suri V, Das P, Pathak P et al (2009) Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-oncology 11(3):274–280. doi:10.1215/15228517-2008-092
48. Taylor KR, Mackay A, Truffaux N et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46(5):457–461. doi:10.1038/ng.2925
49. Weber RG, Hoischen A, Ehrler M et al (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26(7):1088–1097. doi:10.1038/sj.onc.1209851
50. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379. doi:10.1016/S1470-2045(13)70168-2
51. Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403. doi:10.1016/S1470-2045(14)70011-7
52. Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253. doi:10.1038/ng.1102
53. Wu G, Diaz AK, Paugh BS et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46(5):444–450. doi:10.1038/ng.2938
54. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710